PLX324646

GSE99116: Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

  • Organsim human
  • Type RNASEQ
  • Target gene
  • Project ARCHS4

We compared three CDK4/6 inhibitors that have recently emerged as highly promising agents for advanced breast cancers by performing transcriptional profiling (mRNA-Seq) on a panel of seven breast cancer cell lines following 6 or 24 hours of drug exposure at concentrations ranging from 0.3 to 3.0 uM. SOURCE: Peter Sorger (peter_sorger@hms.harvard.edu) - Sorger lab Harvard Medical School

View on GEOView in Pluto

Key Features

Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.

Learn More

14K+ Published Experiments

Access an extensive range of curated bioinformatics data sets, including genomic, transcriptomic, and proteomic data.

Easy Data Import

Request imports from GEO or TCGA directly within Pluto Bio. Seamlessly integrate external data sets into your workflow.

Advanced Search Capabilities

Utilize powerful search tools to quickly find the data sets relevant to your research. Filter by type, disease, gene, and more.

Analyze and visualize data for this experiment

Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.

Read about post-pipeline analysis

View QC data and experiment metadata

View quality control data and experiment metadata for this experiment.

Request import of other GEO data

Request imports from GEO or TCGA directly within Pluto Bio.

Chat with our Scientific Insights team